Characterization of ductal carcinoma in situ cell lines established from breast tumor of a Singapore Chinese patient

Jacklyn WY Yong†, Meng Ling Choong†, SiFang Wang, Yu Wang, Shermaine QY Lim and May Ann Lee*

Abstract

Background: Five cell lines were established from a Singaporean patient of Chinese origin with breast ductal carcinoma in situ (DCIS). These five cell lines express exogenous human telomerase reverse transcriptase (hTERT) which confers the ability to proliferate indefinitely.

Methods: Cells were isolated from the DCIS excision and transfected with a plasmid expressing hTERT, a catalytic subunit of telomerase. Five immortalized colonies were propagated and characterized by karyotyping, array comparative genomic hybridization (CGH), immunostaining and Western blots for biomarkers, in vitro anchorage independent growth, in vivo mouse tumorigenicity, drug sensitivity, species authentication and virology safety testing.

Results: Array CGH analysis showed that the cell lines harbored different specific genetic aberrations. Common mutations observed in most breast cancer cell lines such as the general loss of heterozygosity (LOH) throughout chromosome X and chromosome 17 are also observed in our cell lines. The cell lines were further characterized as human breast cells that are estrogen- and progesterone-receptor positive, and sensitive to tamoxifen. The cell lines showed anchorage-independent growth in the soft agar assay and can grow in common culture medium without supplementation with growth factor, therefore demonstrating transformed characteristics. Four of the cell lines can engraft and form measureable tumors after 50 days when injected subcutaneously into immune-deficient (SCID) mice. The weak tumorigenicity of these cell lines corresponded well with their non-malignant growth origin. The cell lines were authenticated to be of human origin based on DNA fingerprint of the cells. The cell lines were free from contamination of 20 viruses and mycoplasma in the virological safety test panel.

Conclusions: Unlike most available breast cell lines, our cell lines are derived from primary breast cancer tissues that represent earlier grades or tumor progression stages. They would be useful as study models for basic and clinical research programs directed at early diagnosis and intervention.

Keywords: Immortalization, Telomerase, Breast cancer, Ductal carcinoma in situ, Tumorigenicity, Estrogen, Progesterone, Cell line, Chinese

* Correspondence: malee@etc.a-star.edu.sg
† Equal contributors
Cell-Based Assay Development Group, Experimental Therapeutics Centre, Agency for Science Technology and Research, 31 Biopolis Way, #03-01 Nanos Building, Singapore 138669, Singapore

© 2014 Yong et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
There are many benefits in using primary cell cultures with little or no laboratory-induced transformation. The behaviors of these cells are hence more truly reflective of the organ of origins. However, the slow population doubling time and the finite lifespan of these primary cells hinder large scale experimentation that require continuous supply of cells with consistent behavior. Primary cultures require supplementation of growth factors and bovine pituitary extract which are costly and suffer from batch to batch variations. There is also ethical pressure on scientists to reduce the use of animal in laboratory research.

On the other hand, immortalized cell lines are the in vitro equivalent of cancerous cells as they maintained many characteristics of the cancer tissue from which it was derived. Cancer occurs when a somatic cell which normally cannot divide undergoes alterations which cause de-regulation of the normal cell cycle controls leading to uncontrolled proliferation. Immortalized cell lines have undergone similar alterations allowing a cell type which would normally not divide to proliferate in vitro. Cell lines continue to be used as models for medical research due to their ease of use and storage, and consistent cell behavior.

The most commonly used breast cancer cell line in the world is MCF-7. This, together with other commonly used breast cell lines such as the MDA-MB-series, are not derived from primary breast tumors but from tumor metastases in pleural effusions (reviewed in Burdall et al. [1]). Cells from metastatic tumors are often more aggressive than cells in the primary lesion. Results obtained through research work based on these cell lines should be interpreted as late-stage or higher grade breast cancers. However, current clinical practices lead to early diagnosis and treatment of breast cancers. Hence, there is a need for cell lines derived from primary tissues that represent the earlier grades of tumor progression stages. This would be more clinically relevant as most drug therapies are directed at these stages.

We have established five sub-lines derived from primary tissue obtained from a Singapore female patient with ductal carcinoma in situ, a common type of non-invasive breast cancer. The five sub-lines were obtained following over-expression of the human telomerase reverse transcriptase (hTERT) in primary cells. hTERT alone can immortalize cells without causing cancer-associated changes or altering phenotypic properties [2]. Establishment and characterization of these new cell lines were a lengthy process that took a couple of years to complete. Continuous cell lines have undergone significant mutations to become immortal. This can alter the biology of the cell and must be taken into consideration in any analysis. The recognized criteria of a bona fide continuous cell line [3] such as altered cyto-morphology, higher growth rate, reduced growth factor dependency, ability for anchorage independent growth, changes in ploidy, tumorigenicity and an infinite lifespan are documented in this report. These cell lines would be useful in drug screening of early stage breast cancer.

Results
Authentication and virology testing of ETCC001
The Cancer Cell Isolation kit (Panomics) was used to isolate cancer cells from tissue obtained from a Singapore female with breast ductal carcinoma in situ. The resulting cell line was named ETCC001. ETCC001 cells were grown and maintained in M171 media. To verify the species origin of ETCC001, the cells were sent to IDEXX Laboratories, Minnesota, USA for STR DNA fingerprinting and PCR species evaluation. The alleles for nine different STR markers were established (Figure 1A). The result showed that ETCC001 is of human origin and is free from mammalian inter-species contamination (Figure 1B). ETCC001 is also not contaminated with the viruses tested (Figure 1C).

Karyotyping for ETCC001 was performed when the cells were at passage 40. Majority of the karyograms (14 out of 20 metaphases) depicted a normal karyotype (Figure 1D). Of the four karyograms showing trisomy 20, one demonstrated an aberration at chromosome 13 in addition to trisomy 20 (Figure 1D iii). In addition, metaphases containing trisomy 5 (Figure 1D iv) and 12 (Figure 1D v) were observed. The karyograms of ETCC001 confirmed that the cells were of female origin and that majority of the cells have normal karyotypes. However, clonal and non-clonal numerical chromosomal abnormalities were present, which probably provided the basis for the transformation and tumorigenesis.

hTERT immortalization and cell transformation
As M171 is a specialized medium used to culture primary human mammary cells, we determined whether ETCC001 could grow in RPMI supplemented with 10% FBS. However, ETCC001 was unable to grow in RPMI, suggesting that it was not transformed. Hence pGRN145 plasmid containing hTERT (telomerase reverse transcriptase, a catalytic subunit of telomerase) was transfected into ETCC001 cells. The pGRN145 plasmid contains a hygromycin resistance gene. Transfected ETCC001 cells were seeded in 15-cm plates. After two weeks, five hygromycin-resistant clones were obtained and named ETCC006, ETCC007, ETCC008, ETCC010 and ETCC011. There was a dramatic increase of telomerase activity in ETCC006, ETCC007, ETCC008, ETCC010 and ETCC011, compared to ETCC001 (Figure 2A). The clone ETCC011 showed the highest telomerase activity.

Over-expression of the TERT component of telomerase confers replicative immortality such that cells over-expressing it would continue to proliferate indefinitely.
To determine if the over-expression of hTERT and subsequent increase in telomerase activity can affect the population doubling rate and hence cell growth, the population doubling rates of the clones were determined. Figure 2B shows that ETCC001 can reach 50% confluency before growth stagnation while all the other cell lines can reach 100% confluency. A hallmark of transformed cells is the ability to grow to high density due to reduced contact-inhibition. In addition, the population doubling rates of the derived cell lines are similar to that of untransformed ETCC001, while ETCC008 and ETCC011 have distinct faster doubling rate compared to ETCC001. It should be noted that these transformed cell lines are capable of growth in RPMI1640 without growth factor supplements while ETCC001 can only grow in M171 medium supplemented with MEGS.

The average population doubling time of ETCC001 and the cell lines are about 20 hours (Figure 2B). The passage numbers of the cells were 131 for ETCC001, 93 for ETCC006, 86 for ETCC007, 53 for ETCC008, 83 for ETCC010 and 88 for ETCC011 at the time this manuscript was prepared. We passaged the cells every three to four days. This translates to more than 400 population doublings for ETCC001 and more than 200 population doublings for the five hTERT-expressing cell lines at the time of writing this manuscript.

Anchorage-independent growth is another hallmark of cell transformation and is the gold standard used to
detect transformed malignant cells in vitro. All hTERT-transformed cells formed colonies in the soft agar with ETCC006 and ETCC007 forming the highest number of colonies (Figures 2C and D). ETCC001 did not form any colony in the soft agar assay, suggesting it has not acquired a transformed phenotype.

Cell biomarkers

We characterized the cell lines for molecular markers. Pan-cytokeratin (CK) is commonly used as an epithelial cell marker and it was used to determine whether the origin of cell lines are epithelial cells [5]. The cells were also tested for the presence of estrogen receptor (ER) and progesterone receptor (PR) as these receptors are important in determining the course of treatment of breast cancer [6]. MCF7, an epithelial breast cancer cell line, was used as the control. Western blot results (Figure 3A) showed that the six cell lines expressed pan-CK, CK-19, vimentin, ER alpha, ER beta and PR. The level of expression of these markers varies between the cell lines.

To confirm the results of the Western blots and to check for other markers for the epithelial cells, immunofluorescence assays were done (Figure 3B). The epithelial membrane antigen (EMA), an epithelial cell marker was included in addition to pan-CK [6]. EMA and CK-19 are markers for breast cancer cells [7,8]. EMA, pan-CK and CK-19 were detected in all cell lines showing that the cells are of epithelial origin (Figure 3B).

Genomic analysis

Genomic analysis was performed on the cells (ETCC001 at passage 100 and the hTERT-expressing cell lines at passage 50–60) to determine if they contained genomic mutations commonly found in breast cancer. Digital karyograms documenting the gene gain, gene loss and loss of heterozygosity (LOH) are shown in Figure 4. Genetic changes of selected cancer causal gene [9,10] are shown in Table 1. LOH was generally observed in chromosome X in all the cell lines. There were significant gene gains in chromosome 5 in ETCC006 and ETCC007. This coincided with gain in APC (5q21) and TERT (5p15) gene copy numbers observed in ETCC006, ETCC007 and
Figure 3 Determination of cell markers by (A) Western blot and (B) immunofluorescence. ETCC001 and the hTERT transfected cell lines expressed various markers. MCF7 cells were used for comparison to our DCIS cell lines. In the Western blot, the pan cytokeratins antibody could detect multiple cytokeratins in MCF7 cells but our cell lines expressed only 1–2 of these cytokeratins. DAPI was used to stain nucleus in the immunofluorescence study. Images were captured with Zeiss LSM 5 Meta microscope at 100x magnification. Pan-CK: Pan-cytokeratin; CK19: cytokeratin 19; ER: estrogen receptor; PR: progesterone receptor; EMA: epithelial membrane antigen.
ETCC011. Significant LOH was observed in chromosome 17 in ETCC006, ETCC007, ETCC010 and ETCC011. Figure 3B showed a list of published cancer-causal genes identified from various primary tumor tissues [9]. CGH analysis revealed that the hTERT transformed cell lines contained more genetic changes than ETCC001. There were gene loss and/or LOH of TP53 (17p13) and copy number neutral LOH in MAP2K4 (17p11) in all cell lines except ETCC008. Copy number neutral LOH in BRCA1 (17q21) is observed in ETCC007, ETCC010 and ETCC011. The gene for a regulatory subunit of protein kinase A, PRKAR1A (17q23), was loss or LOH in ETCC007, ETCC010 and ETCC011.

Mouse tumorigenicity study
These cell lines showed differences in their growth pattern and acceptance rate. ETCC001 and ETCC008 did not show any tumor growth and were observed to be non-tumorigenic up to 90 days. ETCC006, ETCC007, ETCC010 and ETCC011 cell lines are tumorigenic and vary in their acceptance rate and tumor growth pattern. Mice injected with ETCC011 and ETCC007 exhibited overall good acceptance (8/8) and take rate (100%) whereas the animals injected with ETCC010 and ETCC006 exhibited lower take rate of 87.5% (7/8) and 75% (6/8) respectively. Tumor volume and body weight data are represented in Figure 5A and B. Histology analyzes revealed that the epithelial cells are arranged in densely packed solid pattern and are well differentiated with varying size and shape (Figure 5C).

Drug sensitivities of the cell lines
The cells were treated with compounds commonly used for breast cancer therapy in the clinics. In general, the cell lines were not sensitive to small molecule inhibitors paclitaxel, 5-fluorouracil, gemcitabine, cisplatin and
Table 1 Array CGH was performed to determine chromosomal changes in the DCIS cell lines

| No. | Gene | ETCC001 | ETCC006 | ETCC007 | ETCC008 | ETCC010 | ETCC011 | Location |
|-----|------|---------|---------|---------|---------|---------|---------|----------|
| 1   | ABL1 | -       | -       | -       | -       | -       | -       | 9q34.1    |
| 2   | ABL2 | -       | -       | -       | -       | -       | -       | 1q24-q25  |
| 3   | ALPK2| -       | -       | -       | Loss(1) | -       | -       | 18q21.31q |
| 4   | APC  | -       | Gain(3) | Gain(3) | -       | -       | Gain(3) | 5q21-q22  |
| 5   | ATM  | -       | -       | -       | -       | -       | -       | 11q22.3   |
| 6   | BCR  | -       | -       | -       | -       | -       | -       | 22q11.21  |
| 7   | BMPR1A| -      | -       | -       | -       | -       | -       | 10q22.3   |
| 8   | BRAF | -       | -       | -       | -       | -       | -       | 7q34      |
| 9   | BRCA1| -       | -       | CNLOH   | -       | CNLOH   | CNLOH   | 17q21     |
| 10  | BRCA2| -       | -       | -       | -       | -       | -       | 13q12.3   |
| 11  | CDK4 | -       | -       | -       | -       | -       | -       | 12q14     |
| 12  | CDKN2A| -     | -       | -       | -       | -       | -       | 9p21      |
| 13  | CHEK2| -       | -       | -       | -       | -       | -       | 22q12.1   |
| 14  | CREBBP| -    | -       | -       | -       | -       | Gain(3) | 16p13.3   |
| 15  | CTNNB1| -   | -       | -       | -       | -       | -       | 3p21      |
| 16  | CTNNBIP1| - | -       | -       | -       | -       | -       | 1pter-p36.31 |
| 17  | EGFR | -       | -       | -       | -       | -       | -       | 7p12      |
| 18  | EIF4E| -       | -       | -       | -       | -       | -       | 4q21-q21  |
| 19  | EP300| -       | -       | -       | -       | -       | -       | 22q13     |
| 20  | ERBB2| -       | -       | CNLOH   | -       | -       | CNLOH   | 17q21.1   |
| 21  | ETV6 | -       | -       | -       | -       | -       | -       | 12q13     |
| 22  | FGFR1| CNLOH   | CNLOH  | CNLOH  | CNLOH  | -       | CNLOH   | 8p11.2-p11.1 |
| 23  | FGFR2| -       | -       | -       | -       | -       | -       | 10q26     |
| 24  | FGFR3| -       | -       | -       | -       | -       | -       | 4p16.3    |
| 25  | FHT  | -       | -       | -       | -       | -       | -       | 3p14.2    |
| 26  | FLT3 | -       | -       | -       | -       | -       | -       | 13q12     |
| 27  | HRAS | -       | -       | -       | -       | -       | -       | 11p15.5   |
| 28  | KIT  | -       | -       | -       | -       | -       | -       | 4q11-q12  |
| 29  | KRAF2| -       | -       | -       | -       | -       | -       | 12p12.1   |
| 30  | MAP2K4| -   | Loss(1)/LOH | CNLOH  | -       | CNLOH  | CNLOH  | 17p11.2   |
| 31  | MAPK11| -   | -       | -       | -       | -       | -       | 22q13.33  |
| 32  | MAPK12| -   | -       | -       | -       | -       | -       | 22q13.3   |
| 33  | MAPK13| -   | -       | -       | -       | -       | -       | 6p21      |
| 34  | MAPK14| -   | -       | -       | -       | -       | -       | 6p21.3-p21.2 |
| 35  | MET  | -       | -       | -       | -       | -       | -       | 7q31      |
| 36  | MLL  | -       | -       | -       | -       | -       | -       | 11q23     |
| 37  | MTOR | -       | -       | -       | -       | -       | -       | 1p36      |
| 38  | MYC  | -       | -       | -       | -       | -       | -       | 8q24.12-q24.13 |
| 39  | MYST3| -       | -       | -       | -       | -       | -       | 8p11      |
| 40  | NRAS | -       | -       | -       | -       | -       | -       | 1p13.2    |
| 41  | NTRK1| -       | -       | -       | -       | CNLOH  | 14q21-q22 |
| 42  | NTRK3| -       | -       | -       | -       | CNLOH  | 15q24-q25 |
| 43  | PAX8 | -       | Loss(1)| -       | Loss9(1)| -       | -       | 2q12-q14  |
| 44  | PDGFR | -       | -       | -       | -       | -       | -       | 4q12      |
camptothecin (Table 2). The cell lines were sensitive to
doxorubicin with the exception of ETCC007 and
ETCC008. The presence of the estrogen and progester-
one receptors suggests that the growth of the cell lines
could be regulated by hormones and the use of hormone
suppressors could negatively regulate the proliferation of
these cells. Indeed, our cell lines were sensitive to estro-
gen receptor antagonist Tamoxifen. This finding corre-
lates well with the presence of estrogen receptor on
these cell lines as demonstrated by immunostaining and
Western blot results. Monoclonal antibody (Herceptin)
against human epidermal growth factor receptor 2 (Her2),
is not cytotoxic to the cell lines up. This may suggest that
there is no Her2 amplification in the cells. Her2-negative
breast cancers tend to be less aggressive [11] and this cor-
relates well with our cell lines which are derived from a
subject with breast ductal carcinoma in situ.

Discussion
In this study, we have established 5 cell lines from pri-
mary cells from breast cancer tissue obtained from a
Chinese female patient of Singapore origin. The primary
cell line, ETCC001, is confirmed to be of human origin
and free from inter-species contamination.

Cell lines are widely used in many aspect of laboratory
research. It has been reported that 18% of new cell lines
deposited at the German Cell Line Bank were found
to be cross-contaminated [12]. It is important to ensure
that the cell lines established in our laboratory are
well characterized with their identities confirmed prior
to using these cell lines for further research. However,
tests such as isoenzyme typing, karyotyping, or DNA fin-
gerprinting can be time consuming and costly. Using
multiplex PCR, STR profiling with a standard set of STR
primers has been proposed as a reliable and cost effect-
ive method for cell line identification [13]. In this report,
9 STR loci have been selected [14] and tested for their
high discrimination when used in combination (1 in 108
discrimination rate for unrelated individuals).

Breast tumor biopsies are heterogeneous and it is pos-
sible that the derived cell lines could be contaminated
with fibroblasts and normal epithelial cells. In order to
rule out these possibilities, we have performed magnetic
sorting for fibroblasts and surface marker analyses of the
cell lines. The cell lines exhibit typical epithelial markers
(pan-CK) as well as epithelial cancer markers CK19 and
EMA [7,8].

Human mammary epithelial cells have been found to
stop dividing at 55–60 population doublings. Transfec-
tion of these cells with hTERT are found to extend cell
division to over 250 population doublings [15]. In our
case, the expression of hTERT has allowed the cell lines

Table 1 Array CGH was performed to determine chromosomal changes in the DCIS cell lines (Continued)

| Gene   | Chromosome | Band | Copy Number | LoH |
|--------|------------|------|-------------|-----|
| 45     | PIK3CG2G   |      |             |     |
| 46     | PIK3CA     |      |             |     |
| 47     | PIP        |      |             |     |
| 48     | PRARG      |      |             |     |
| 49     | PRCC       |      |             |     |
| 50     | PRKRA1A    |      | CNLOH       | CNLOH CNLOH|
| 51     | PRKCB      |      |             |     |
| 52     | PTEN       |      |             |     |
| 53     | RB1        |      |             |     |
| 54     | RET        |      |             |     |
| 55     | SMAD4      |      |             |     |
| 56     | SCGB2A2    |      |             |     |
| 57     | SCGB2A1    |      |             |     |
| 58     | STR11      |      |             |     |
| 59     | TCF4       |      |             |     |
| 60     | TERT       |      | Gain(3)     | Gain(3) |
| 61     | TFF1       |      |             |     |
| 62     | TP53       |      | Loss(1)/LOH | CNLOH |
| 63     | VHL        |      |             |     |
| 64     | WWOX       |      |             |     |

Genetic changes in selected cancer causal genes are shown. Numbers in parentheses represent copy number of the gene. CNLOH: copy number neutral loss of heterozygosity.
to grow and proliferate in culture medium RPMI1640 not supplemented with growth factors and hormones. While it appears that the level of telomerase activity in the cells does not correlate with population doubling rate, all the cells were able to reach 100% confluency in culture in contrast to ETCC001, which can only reach 50% confluency before growth stagnation. We have successfully propagated these transformed cells to high passage numbers (see Results) and are able to grow them in the RPMI1640 medium without growth factor supplements. This demonstrates that the cells are immortalized and are capable of continuous growth.

We report here the establishment of breast cell lines from non-invasive breast DCIS that express both ER and PR. Most common breast cell lines such as the MDA-MB-XXX series, BT20, SkBr3 and ZR75.1 do not express ER and PR. On the other hand, there are fewer choices of cell lines positive for the expression of ER and PR, examples being MCF-7 and T47D. Even though MCF7 and T47D express both ER and PR, they are of metastatic origin and are derived from lung pleural effusion [1]. Some recent examples of ER and PR positive breast cell lines are MBC1 and MBC2 derived from Malaysian patients [16] and BC-019, BC-020 and BC-021 from Chinese patients [17]. However, unlike our cell lines, both the Malaysian breast cell lines (MBC1 and MBC2) and the Chinese cell lines (BC-019, BC-020 and BC-021) are derived from breast tissues with invasive breast ductal carcinoma [16,17]. Other examples of breast DCIS cell lines are DCIS.COM [18] derived from ras-transformed MCF-10AT cells from fibrocystic breast

![Figure 5 Tumorigenicity of cell lines in SCID mice. (A) Tumor size and (B) body weight of injected SCID mice were measured twice weekly. ETCC001 does not form tumor while the hTERT expressing ETCC008 form palpable tumors that were less than 30 mm³. (C) Histological images of the tumors performed at the end of the experiment show the epithelial cells arranged in densely packed solid pattern that were well differentiated with varying size and shape (H&E stained, 40X magnification).](image-url)
of the cells. The result shown is representative of a single experiment. BRCA1 has been reported to be associated with human breast cancer [21,22] and other cancers [23–25]. BRCA1 participates in the maintenance of X-chromosome inactivation. The loss of the BRCA1 wild-type allele inherited from the unaffected parent through LOH represents the event that initiates the tumorigenesis process observed in primary breast and ovarian tumors [26]. We have observed BRCA1 copy number neutral LOH in three of the derived cell lines. Chromosome 17 is also a chromosome that suffers most LOH and/or loss of genes in all the derived cell lines. Besides BRCA1, other important cancer causal genes on chromosome 17 such as TP53, MAP2K4, ERBB2 and PRKAR1A [9] are all observed to have loss or copy number neutral LOH in these cell lines. Deletions of functional copies of MAP2K4 and BRCA1 have also been reported in several breast cancer cell lines [27]. This may explain the transformation of the cells leading to immortalization. hTERT levels do not correlate to the amount of genetic aberrations observed in each cell lines. However, the amount of genetic aberrations seems to correlate with the ability of the cells to form colonies in soft agar and tumorigenicity in SCID mice.

Table 2 Drug sensitivity of ETCC001 and sub-lines

| Anti-neoplastic Class | IC50 (μM) |
|-----------------------|-----------|
|                       | ETCC001   | ETCC006 | ETCC007 | ETCC008 | ETCC010 | ETC011 | MCF7 |
| ER antagonist         | 6.3       | 34.2    | 32.8    | 32.4    | 30.0    | 33.5   | 26.6 |
| Monoclonal Ab         | >10       | >10     | >10     | >10     | >10     | >10    | Not Done |
| Anti-microtubular     | Paclitaxel| >100    | >100    | >100    | >100    | >100   | >100 |
| Anti-metabolite       | 5-fluorouracil| >100 | >100    | >100    | >100    | >100   | >100 |
| Anti-metabolite       | Gemcitabine| >100   | >100    | >100    | >100    | >100   | >100 |
| Alkylating            | Cisplatin | >100    | >100    | >100    | >100    | >100   | >100 |
| Anthracycline         | Doxorubicin| 9.3     | 3.2     | >100    | 77.8    | 5.0    | 20.8 |
| Topo I inhibitor      | Camptothecin| >100   | >100    | >100    | >100    | >100   | >100 |

ER: estrogen receptor; Ab: antibody; Topo: topoisomerase

Cells were treated with common chemotherapeutic agents and viability of the cells was determined by measuring cellular ATP levels after 48 hours. Concentration of drug (in μM) which inhibits 50% cell viability (IC50) is shown. The experiments were carried out in triplicates and repeated on different passages of the cells. The result shown is representative of a single experiment.

tissue, SUM225 [19] derived from chest wall recurrence of a DCIS patient treated with mastectomy, and hDCIS.01 [20] from breast columnar cell hyperplasia. Of these, only hDCIS.01 cells are positive for ER and PR expression.

Karyotyping with GTL-bandimg of metaphase cells shows that ETCC001 is heteroploid with multiple chromosomal abnormalities. Our CGH analysis also shows chromosomal variations among the cell lines. We observed LOH on the X-chromosomes on ETCC001 and all its derived cell lines. LOH on the X-chromosome have been reported to be associated with human breast cancer [21,22] and other cancers [23–25]. BRCA1 participates in the maintenance of X-chromosome inactivation. The loss of the BRCA1 wild-type allele inherited from the unaffected parent through LOH represents the event that initiates the tumorigenesis process observed in primary breast and ovarian tumors [26]. We have observed BRCA1 copy number neutral LOH in three of the derived cell lines. Chromosome 17 is also a chromosome that suffers most LOH and/or loss of genes in all the derived cell lines. Besides BRCA1, other important cancer causal genes on chromosome 17 such as TP53, MAP2K4, ERBB2 and PRKAR1A [9] are all observed to have loss or copy number neutral LOH in these cell lines. Deletions of functional copies of MAP2K4 and BRCA1 have also been reported in several breast cancer cell lines [27]. This may explain the transformation of the cells leading to immortalization. hTERT levels do not correlate to the amount of genetic aberrations observed in each cell lines. However, the amount of genetic aberrations seems to correlate with the ability of the cells to form colonies in soft agar and tumorigenicity in SCID mice.

One of the definitive assays to determine whether cells are transformed is anchorage-independent growth. All cell lines, except ETCC001, can form colonies in soft agar. This suggests that ETCC001 is untransformed while the cell lines over-expressing hTERT are transformed. hTERT levels do not correlate with the ability of the cells to form colonies in soft agar and tumorigenicity in SCID mice. It is likely that the changes in gene copy number observed in the CGH study could have contributed to their ability to grow in the soft agar. Extended number of cell doublings through bypassing cellular senescence would allow accumulation of genetic changes favoring cell survival. Extension of lifespan by telomerase was reported to select for c-myc over-expression in human mammary epithelial cells [15]. We have shown using CGH analysis that the five cell lines generated with hTERT transformation have more genomic changes than the original cell line.

Our hTERT-transformed cell lines can form colonies in soft agar but are only weakly tumorigenic in the SCID mice. The weak tumorigenicity in SCID mice is representative of its origin as a non-invasive breast ductal carcinoma in situ. Cells derived from certain epithelial tissues have been reported to have in vitro anchorage-independent phenotype that is not associated with tumorigenicity [28]. These exceptional cells may express new cell surface antigens leading to the inhibition of tumor growth by the residual immune response or non-specific killer lymphocytes [29] in the SCID mice. These observations led to the hypothesis that the loss of the anchorage requirement in vitro, for example in the soft agar assay, is a necessary but not a sufficient correlation of cellular malignancy.

Sensitivities toward tamoxifen and doxorubicin have decreased in the hTERT-expressing cell lines compared to the primary ETCC001 cell line. This could be due to more genetic aberrations in the hTERT-expressing cell lines leading to loss of tumor suppressors and/or activation of oncogenes as discussed above. However, this does
not imply a loss of the DCIS identity as we still observed weak tumorigenicity in SCID mice with these hTERT-expressing cell lines which is consistent with the non-invasive nature of DCIS in early phase breast cancer.

Conclusions
We have established five cell lines from a patient with breast ductal carcinoma in situ. The cell lines were derived from cells that have been stably transformed with hTERT. A compendium of genetic, physical and molecular characterizations has demonstrated that the five cell lines carry distinct genetic changes. The cell lines also express estrogen and progesterone receptors, CK19, EMA and other surface biomarkers, confirming that they are of breast epithelial origin. The cell lines together with the information that we have acquired will provide a rich resource in drug discovery and cell physiology studies for early stage breast cancer.

Methods
Cancer tissues and reagents
Tissue was obtained from breast ductal carcinoma in situ (DCIS) of a 47 year-old female of Chinese origin. The Cancer Cell Isolation Kit (Panomics) was used to obtain primary cells from the tissue. Fibroblasts were removed using the MAC Separator (Miltenyi Biotech). Primary cells obtained were labeled as ETCC001 and were grown in M171 media (Life Technologies) with mammary epithelial growth supplement (MEGS). Cell lines arising from ETCC001 after hTERT transformation were grown in RPMI supplemented with 10% fetal bovine serum (FBS), L-glutamine and Penicillin/Streptomycin. Cells that arose from ETCC001 after hTERT transformation were grown in RPMI supplemented with 10% fetal bovine serum (FBS), L-glutamine and Penicillin/Streptomycin. Cells cultures were maintained in a humidified incubator at 37°C with 5% atmospheric CO2.

hTERT transfection and generation of stable clones
pGRN145 vector containing hTERT expression plasmid (ATCC) and hygromycin resistant gene was used to transfect ETCC001 primary cells. Transfection was performed using Lipofectamine 2000 (Life Technologies). 30 μg/ml of Hygromycin (Life Technologies) was used to select for positively transfected cells. 1 × 10^6 hygromycin-resistant cells were seeded in a 15-cm petri dish and grew for at least 2 weeks. Single cell colonies were then amplified. Telomerase activity in these cell colonies was measured using the TRAPEze Telomerase Detection Kit (Millipore). Heat inactivated samples were used as negative controls for the telomerase activity detection.

Cell line authentication and virology safety testing
ETCC001 cells in metaphase were fixed and stained for Giemsa/Tryptsin/Leishman (GTL)-banding to obtain karyograms (Cytogenetics laboratory, National University Hospital, Singapore). Cell pellets were also sent to IDEXX Laboratories Inc (Columbia, Minnesota) for further authentication and virological safety testing. Short tandem repeat (STR) analysis were done to establish cell line identity, inter-species (rat, mouse, Chinese hamster, African Green Monkey). The cell lines were tested for contaminations by polymerase chain reaction (PCR) screening for 18 types of virus, and mycoplasma.

Western blot and immunofluorescence staining for cell markers
Western blot and Immunofluorescence staining were performed to detect breast and epithelial cell markers. Primary antibodies used were mouse anti-EMA (Dako), rabbit anti-Pan-Ck (Abcam), rabbit anti-Ck19 (Abcam), mouse anti-estrogen receptor (ER) α (Abcam), rabbit anti-ERβ (Abcam) and mouse anti-progesterone receptor (PR) (Abcam). Secondary antibodies used in Western blot analysis were horse-radish peroxidase conjugated goat anti-rabbit and anti-mouse antibodies (Dako). Secondary antibodies used in immunofluorescence study were Alexa Fluor 594 goat anti-rabbit (Life Technologies) and Alexa Fluor 488 goat anti-mouse (Life Technologies). Antibody concentrations used in Western blot and immunofluorescence staining were as recommended by the antibody manufacturers.

Cell doubling time
Cell doubling time was determined using the IncuCyte real-time cell analyzer (Essen Bioscience). The Incucyte uses cell confluency as a measure of cell growth. 1 × 10^5 cells were seeded in 24-well plates. Each well contained 0.6 ml of 0.6% agar (Sigma) in complete medium in the bottom layer, 0.5 ml of 0.36% agar in complete medium with cells in the middle layer, and covered with 0.5 ml medium. The cells were cultured at 37°C with 5% atmospheric CO2, for 2 to 3 weeks. After overnight staining with tetrazolium dye, MTT (Sigma) at 70 μl per well at 5 mg/ml, the colonies were counted using the GelCount® instrument (Oxford Optronix).
Mouse tumorigenicity study

10 × 10^6 cells from ETCC001 and the five hTERT-expressing cell lines were injected subcutaneously into the right flank of each female SCID mice (age 6–8 weeks). Eight mice were injected for each cell lines. All the animals were observed for clinical signs, body weight, tumor volume & mortality. Clinical signs, body weight and tumor volume were recorded twice weekly throughout the experiment. The mice were sacrificed at the end of the experiment. A piece of each palpable tumor was snap frozen or fixed in 10% Neutral-buffered formalin solution for histopathology study by hematoxylin and eosin (H&E) staining. The study was carried out at the A-STAR Biological Resource Center - an Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC) accredited facility. All animals were handled humanely with due regard for their welfare. The study was designed to use the fewest possible number of animals. The study design was reviewed and approved by the Institutional Animal Ethics Committee.

Drug treatment

Tamoxifen, paclitaxel, 5-fluorouracil, gemcitabine, cisplatin, doxorubicin and camptothecin were purchased from Calbiochem, and hepcertin was purchased from Roche. Cells were seeded in 50 μl medium in 96-well plates at 8000 cells/well and incubated overnight. Compounds (50 μl) were added to cells and incubated for 48 hours.100 μl of CellTiter-Glo (Promega) was added to the cells. After 10 minutes of incubation at room temperature, luminescence was measured with Safire II plate reader (Tecan). Drug treatment

Abbreviations

AAALAC: Association for Assessment and Accreditation of Laboratory Animal Care; A-STAR: Agency for Science Technology and Research; CK19: Cytokeratin 19; DCIS: Ductal carcinoma in situ; EMA: Epithelial membrane antigen; ER: Estrogen receptor; GTL: Giemsa/trypsin/Leishman; H&E: Hematoxylin and eosin; Her2: Epidermal growth factor receptor 2; hTERT: Human telomerase reverse transcriptase; LOH: Loss of heterozygosity; Pan-CK: Pan-cytokeratin; PCR: Polymerase chain reaction; PR: Progesterone receptor; SD: Standard deviation; STR: Short tandem repeat.

Competing interests

The authors declare having no financial and non-financial competing interests.

Authors’ contributions

JWYY and MLC planned the experiments, conducted most of the experiments, and the writing of the manuscript. SFW, YW and SQYL conducted some experiments under guidance from JWYY and MLC. MAL initiated and supervised the project. All authors read and approved the final manuscript.

Acknowledgement

We acknowledge Dr Eng Chon Boon from the National University Health System of Singapore (NUHS). Tissue Repository in providing the primary tissue used in this article.

References

Burdall SE, Hanby AM, Lansdown MR, Speirs V: Breast cancer cell lines: friend or foe? Breast Cancer Res 2003, 5(3):280–285.
Lee KM, Cho KH, Quellette MM: Use of exogenous hTERT to immortalize primary human cells. Cytotechnology 2004, 45(1–2):33–38.
Freshney RI: Introduction to basic principles. In Animal Cell Culture: A Practical Approach. Edited by Freshney RI. RL Press: Oxford; 1992, 1–14.
Chapman EJ, Hurst CD, Pitt E, Chambers P, Aveyard JS, Knowles MA: Expression of hTERT immortalises normal human urothelial cells without inactivation of the p16/Rb pathway. Oncogene 2006, 25:5037–5045.
Chen MH, Yip GW, Tse GM, Moriya T, Lui PC, Zin ML, Bay BH, Tan PH: Expression of basal keratins and vimentin in breast cancers of young women correlates with adverse pathologic parameters. Mod Pathol 2008, 21(10):1183–1191.
Siewell B, Lansimont D, Lacroix M: Body J- Establishment and characterization of three new breast-cancer cell lines. Int J Cancer 1998, 76:657–660.
Loveday RL, Speirs V, Drew PJ, Kerin MJ, Monson JR, Greenwood J: Intracellular flow cytometric analysis of primary cultured breast tumor cells. Cancer Invest 2002, 20(3):340–347.
Langner C, Ratschek M, Relik H, Schips L, Zigeuner R: Expression of MUC1 (EMA) and E-cadherin in renal cell carcinoma: a systematic immunohistochemical analysis of 188 cases. Mod Pathol 2004, 17(2):182–188.
Futreal PA, Coin L, Marshall M, Down T, Hubbard T, Wooster R, Rahman N, Stratton MR: A census of human cancer genes. Nat Rev Cancer 2004, 4(3):177–183.
Ikedobi ON, Davies H, Bignell G, Edkins S, Stevens C, O’Meara S, Santarius T, Avis T, Barthorpe S, Brackenbury L, Buck G, Butler A, Clements J, Cole J, Dicks E, Forbes S, Gray K, Halliday K, Hilly K, Hinton J, Hunter C, Jenkinson A, Jones D, Kosmidou V, Lugg R, Menzies A, Mironenko T, Parker A, Perry J, et al: Mutation analysis of 24 known cancer genes in the NCI-60 cell line set. Mol Cancer Ther 2006, 5(11):2606–2612.
Tan M, Yu D: Molecular mechanisms of erbB2-mediated breast cancer chemoresistance. Adv Exp Med Biol 2007, 608:119–129.
MacLeod RA, Dirks WG, Matsuo Y, Kauffman M, Milch H, Drexler HG: Widespread intraspecies cross-contamination of human tumor cell lines arising at source. Int J Cancer 1999, 83(4):553–563.
Masters JR, Thomson JA, Daly-Burns B, Reid YA, Dirks WG, Packer P, Toij LH, Ohno T, Tanabe H, Arlett CF, Arlett CF, Kelland LR, Harrison R, Mirmah, A, Ward TH, Ayres KL, Debenham PG: Short tandem repeat repeat profiling provides an international reference standard for human cell lines. Proc Natl Acad Sci U S A 2001, 98(14):8012–8017.
Lins AM, Micka KA, Speicher CJ, Taylor JA, Bacher JW, Rabbach DR, Bever JA, Creacy SD, Schumm JW: Development and population study of an eight-locus short tandem repeat (STR) multiplex system. J Forensic Sci 1998, 43(6):1168–1180.
Wang J, Hannon GJ, Beach DH: Risky immortalization by telomerase. Nature 2000, 405(6882):755–756.
Kamalidehghan B, Houshmand M, Kamalidehghan F, Jafarzadeh N, Azari S, Amsal SN, Rosi R: Establishment and characterization of two human breast carcinoma cell lines by spontaneous immortalization: discordance between Estrogen, Progesterone and HER2/neu receptors of breast carcinoma tissues with derived cell lines. Cancer Cell Int 2012, 12(1):43.
Shen C, Gu M, Liang D, Miao L, Hu L, Zheng C, Chen J: Establishment and characterization of three new human breast cancer cell lines derived from Chinese breast cancer tissues. Cancer Cell Int 2009, 9(2).
Soule HD, Maloney TM, Wolman SR, Peterson WD Jr, Brenz R, McGrath CM, Russo J, Pauley RJ, Jones RF, Brooks SC: Isolation and characterization of a spontaneously immortalized human breast epithelial cell line, MCF-10. Cancer Res 1990, 50(18):6075–6086.
Ignatovski KM, Lapointe AJ, Radany EH, Ether SP: erbB-2 overexpression in human mammary epithelial cells confers growth factor independence. Endocrinology 1999, 140(8):3615–3622.
Feely L, Quinn CM: Columnar cell lesions of the breast. Histopathology 2008, 52(1):11–19.
Loupart ML, Adams S, Armour JA, Walker R, Brammar W, Varley J: Loss of heterozygosity on the X chromosome in human breast cancer. Genes Chromosomes Cancer 1995, 13(4):229–238.
22. Roncuzzi L, Brognara I, Cocchi S, Zoli W, Gasperi-Campani A: Loss of heterozygosity at pseudoautosomal regions in human breast cancer and association with negative hormonal phenotype. Cancer Genet Cytogenet 2002, 135(2):173–176.
23. Brown CJ: Role of the X chromosome in cancer. J Natl Cancer Inst 1996, 88(8):480–482.
24. Shen XJ, Ali-Fehmi R, Weng CR, Sarkar FH, Grignon D, Liao DJ: Loss of heterozygosity and microsatellite instability at the Xq28 and the A/G heterozygosity of the QM gene are associated with ovarian cancer. Cancer Biol Ther 2006, 5(5):523–528.
25. Chen YJ, Vortmeyer A, Zhuang Z, Gibril F, Jensen RT: X-chromosome loss of heterozygosity frequently occurs in gastrinomas and is correlated with aggressive tumor growth. Cancer 2004, 100(7):1379–1387.
26. Feunteun J: [A paradox and three enigmas about the role of BRCA1 in breast and ovarian cancers]. J Soc Biol 2004, 198(2):123–126.
27. Kao J, Salari K, Bocanegra M, Choi YL, Girard L, Gandhi J, Kwei KA, Hernandez-Boussard T, Wang P, Gazdar AF, Minna JD, Pollack JR: Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery. PLoS One 2009, 4(7):e6146.
28. Kahn P, Shin St: Cellular tumorigenicity in nude mice. Test of associations among loss of cell-surface fibronectin, anchorage independence, and tumor-forming ability. J Cell Biol 1979, 82(1):1–16.
29. Herberman RB, Djeu JY, Ortaldo JR, Holden HT, West WH, Bonnard GD: Role of interferon in augmentation of natural and antibody-dependent cell-mediated cytotoxicity. Cancer Treat Rep 1979, 62(11):1893–1896.

Cite this article as: Yong et al.: Characterization of ductal carcinoma in situ cell lines established from breast tumor of a Singapore Chinese patient. Cancer Cell International 2014 14:94.

Submit your next manuscript to BioMed Central
and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at www.biomedcentral.com/submit